South Korea
· Delayed Price · Currency is KRW MiCo BioMed Statistics
Total Valuation
MiCo BioMed has a market cap or net worth of KRW 70.52 billion. The enterprise value is 79.37 billion.
| Market Cap | 70.52B |
| Enterprise Value | 79.37B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MiCo BioMed has 43.56 million shares outstanding. The number of shares has increased by 61.69% in one year.
| Shares Outstanding | 43.56M |
| Shares Change (YoY) | +61.69% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 0.00% |
| Float | 30.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.96 |
| PB Ratio | 3.17 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.74 |
| EV / Sales | 10.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.08 |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of 0.55.
| Current Ratio | 1.89 |
| Quick Ratio | 0.62 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.84 |
| Interest Coverage | -9.88 |
Financial Efficiency
Return on equity (ROE) is -180.34% and return on invested capital (ROIC) is -44.41%.
| Return on Equity (ROE) | -180.34% |
| Return on Assets (ROA) | -33.02% |
| Return on Capital (ROIC) | -44.41% |
| Revenue Per Employee | 96.41M |
| Profits Per Employee | -386.00M |
| Employee Count | 75 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 1.19 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.70% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -62.70% |
| 50-Day Moving Average | 1,863.44 |
| 200-Day Moving Average | 1,672.09 |
| Relative Strength Index (RSI) | 42.74 |
| Average Volume (20 Days) | 2,916,988 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MiCo BioMed had revenue of KRW 7.23 billion and -28.95 billion in losses. Loss per share was -815.05.
| Revenue | 7.23B |
| Gross Profit | -7.70B |
| Operating Income | -23.43B |
| Pretax Income | -29.02B |
| Net Income | -28.95B |
| EBITDA | -21.26B |
| EBIT | -23.43B |
| Loss Per Share | -815.05 |
Balance Sheet
The company has 5.98 billion in cash and 13.10 billion in debt, giving a net cash position of -7.12 billion or -163.50 per share.
| Cash & Cash Equivalents | 5.98B |
| Total Debt | 13.10B |
| Net Cash | -7.12B |
| Net Cash Per Share | -163.50 |
| Equity (Book Value) | 23.95B |
| Book Value Per Share | 510.32 |
| Working Capital | 12.21B |
Cash Flow
In the last 12 months, operating cash flow was -14.87 billion and capital expenditures -751.27 million, giving a free cash flow of -15.62 billion.
| Operating Cash Flow | -14.87B |
| Capital Expenditures | -751.27M |
| Free Cash Flow | -15.62B |
| FCF Per Share | -358.61 |
Margins
| Gross Margin | -106.54% |
| Operating Margin | -323.97% |
| Pretax Margin | -401.33% |
| Profit Margin | n/a |
| EBITDA Margin | -294.05% |
| EBIT Margin | n/a |
| FCF Margin | -216.03% |
Dividends & Yields
MiCo BioMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -61.69% |
| Shareholder Yield | -61.69% |
| Earnings Yield | -50.34% |
| FCF Yield | -22.15% |
Stock Splits
The last stock split was on November 16, 2023. It was a forward split with a ratio of 1.199978.
| Last Split Date | Nov 16, 2023 |
| Split Type | Forward |
| Split Ratio | 1.199978 |
Scores
MiCo BioMed has an Altman Z-Score of -3.71. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.71 |
| Piotroski F-Score | n/a |